Meyahealth
HomeGeneticsGeneNLRP1 gene
Back to Gene
NLRP1 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

NLRP1 gene

The NLRP1 gene provides instructions for a protein that helps regulate inflammation and is associated with several autoimmune conditions.

Normal Function

The NLRP1 gene provides instructions for making a member of the nucleotide-binding domain and leucine-rich repeat containing (NLR) protein family. These proteins help regulate inflammation, a process where the immune system responds to injury or microbial invaders to facilitate tissue repair.

The NLRP1 protein is involved in the assembly of a molecular complex called an inflammasome, which triggers inflammation in response to bacteria or viruses. It is also believed to play a role in apoptosis, or the self-destruction of cells.

Health Conditions Related to Genetic Changes

Vitiligo

Variations in the NLRP1 gene are associated with an increased risk of vitiligo, an autoimmune condition causing patchy loss of skin pigmentation. These variations likely affect the protein's activity, making it difficult for the body to control inflammation and prevent the immune system from attacking pigment-producing cells (melanocytes).

Autoimmune Addison disease

Variations in this gene have been linked to an increased risk of Addison disease, where the immune system attacks the adrenal glands. These variations may lead to an overactive immune system that damages the body's own tissues.

Autoimmune disorders

NLRP1 variations have also been associated with an increased risk of type 1 diabetes, an autoimmune disorder where insulin-producing cells in the pancreas are destroyed due to immune system overactivity.

Genomic Location

The NLRP1 gene is found on chromosome 17.

Frequently Asked Questions

You should monitor for signs specific to target organs affected by NLRP1-associated autoimmunity. For vitiligo, look for progressive, sharply demarcated white patches of skin or premature silver-gray hair on the scalp or eyelashes. For autoimmune Addison disease, early signs include persistent unexplainable fatigue, lightheadedness upon standing, salt cravings, unexplained weight loss, and hyperpigmentation in skin creases or inside the mouth. For type 1 diabetes, watch for excessive thirst, frequent urination, unexplained weight loss, and extreme fatigue.
Currently, there are no approved therapies that exclusively target the NLRP1 protein alone. However, clinicians manage active inflammatory responses using treatments that suppress downstream cytokines generated by the inflammasome, such as interleukin-1 (IL-1) and interleukin-18 (IL-18). For organ-specific autoimmunity, standard therapy remains the mainstay: topical immunomodulators or phototherapy for vitiligo, hormone replacement therapy (hydrocortisone and fludrocortisone) for Addison disease, and insulin regimens for type 1 diabetes.
Most NLRP1 variations associated with conditions like vitiligo or Addison disease follow a complex, polygenic inheritance pattern rather than a straightforward single-gene pattern. This means multiple genes interact together to influence total risk. Because carrying an individual variant does not reliably predict whether a person will become ill, routine genetic screening of asymptomatic family members is generally not clinically indicated unless advised by a geneticist evaluating a broader autoinflammatory syndrome.
No. Variations in the NLRP1 gene are considered susceptibility factors rather than direct causes. Autoimmune disorders are multifactorial, meaning they develop from a combination of inherited genetic predispositions, immune system regulation, and environmental triggers such as viral infections, severe stress, or chemical exposures. Carrying an altered variant increases your statistical risk compared to the general population, but most individuals with these variants never develop a clinical autoimmune disorder.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ